Blog
Tirzepatide Plateau: Why Weight Loss Stalls and What Moves the Scale Again
The first months on tirzepatide usually go fast. Then, somewhere around the fifth or sixth month, the scale slows down, and one weigh-in after another lands within a pound or two of the last. The old hunger starts to come back, the dose is already most of the way up the ladder, and it feels as if the drug has quit.
It hasn’t, and the trials show exactly what is going on. In SURMOUNT-1, the 72-week trial that got tirzepatide approved for weight loss, nearly half the people losing weight on it had reached their plateau by week 24 and close to nine in ten by the end (Horn et al., Clinical Obesity, 2025). A plateau is where tirzepatide’s curve ends for almost everyone. What decides the next move is when it arrived, at which dose, and how far down it came.
Does tirzepatide plateau?
Yes, and on a fairly predictable schedule. Researchers went back through SURMOUNT-1 and marked the point after which each person’s weight never moved more than 5% in any 12-week stretch again. By that measure, 702 of the 1,438 people analyzed had plateaued by week 24, another 567 got there between weeks 36 and 60, and 169, about one in eight, were still losing when the trial stopped at week 72 (Horn et al., Clinical Obesity, 2025).
Starting weight shaped the timing more than anything else. The first 24 weeks took roughly the same share off everyone, 13% to 14.5% of body weight whatever the starting BMI. After that the paths split, and the heavier the start, the longer the loss kept running. Find the row for your starting BMI:
| Starting BMI | Lost by week 24 | Further loss, weeks 24 to 72 | Median plateau week | Plateaued by week 72 |
|---|---|---|---|---|
| 27 to 29.9 | 13.4% | 4.6% | Week 24 | 90% |
| 30 to 34.9 | 14.5% | 7.0% | Week 26 | 89% |
| 35 to 39.9 | 14.3% | 8.8% | Week 36 | 88% |
| 40 and up | 13.3% | 9.7% | Week 36 | 88% |
Dose and sex moved the date as well. Against 5mg, the plateau came 4.4 weeks later on 10mg and 6.7 weeks later on 15mg. Women plateaued 4.2 weeks later than men, and every ten years younger added close to another week. A later plateau was also a deeper one: people who leveled off at week 24 were 12.1% below their starting weight at that point, while those who kept going into weeks 36 to 60 were 24.3% down when they stopped.
A stall around month six, from a lower starting weight, is the textbook case: the trial’s curve, arriving on time.
Tirzepatide plateau after 2, 3 or 4 months
Usually not a plateau yet. Two to four months in, most people are still on the way up the dose ladder, and the pace of the scale always changes once the first drop is over.
The label schedule opens at 2.5mg for four weeks, moves to 5mg, then climbs 2.5mg at a time with at least four weeks per step. On the fastest version of that ladder, month three is 7.5 to 10mg and 15mg arrives around week 20. Each new step also takes a few weeks to build to its full level in the blood. In the SURMOUNT-1 plateau analysis, the earliest plateaus began at week 24.
Two things make months two to four look flatter than they are. The opening drop includes water held with stored carbohydrate, so it always outruns what follows. And body weight swings 1% to 2% from day to day and week to week on water, salt and what is in the gut, which on a 220-pound frame is two to four pounds. A single flat week inside that band says nothing; a trend that stays flat across a month on the same dose does.

Why tirzepatide stops working: the body pushes back
It doesn’t stop. The body adjusts to every kilogram it loses, and the plateau is the point where that push matches tirzepatide’s pull.
Two things change as weight comes off. The body spends a little less, around 30 calories a day for each kilogram lost. Appetite rises by far more: about 100 extra calories a day of drive to eat per kilogram, more than three times the spending side (Polidori et al., Obesity, 2016). Someone 10kg (22 lb) down is holding back something on the order of 1,000 extra calories a day of appetite.
Tirzepatide’s brake is set by the dose, while the push grows with every kilogram. Where the two meet, what is eaten and what is spent even out, and weight holds. The SURMOUNT plateau analysis describes the same turn: the move from losing to maintaining, carried by a lower resting burn and by hunger and fullness hormones shifting against the loss (Horn et al., Clinical Obesity, 2025).
That returning hunger is what makes the drug feel weaker, yet on a steady weekly dose the tirzepatide level in the blood in month nine matches month five. Only the push has grown.
SURMOUNT-4 showed the drug still doing its job at that stage. Everyone took tirzepatide for 36 weeks and lost 20.9% on average, then half were moved to placebo without knowing it. Over the next 52 weeks, the group kept on tirzepatide lost another 5.5%, and the placebo group regained 14.0% (Aronne et al., JAMA, 2024). A plateau on tirzepatide is the drug holding the new weight in place.
Tirzepatide stopped working at the highest dose
15mg is the top of the ladder, and the climb to it adds the least. In SURMOUNT-1, among people who stayed on treatment, 5mg took off 16.0% of body weight over 72 weeks, 10mg 21.4% and 15mg 22.5% (Jastreboff et al., New England Journal of Medicine, 2022). Going from 5 to 10mg bought 5.4 points; the last 5mg bought 1.1.
No dose above 15mg is approved, and every SURMOUNT trial stopped there. Flat for a couple of months on 15mg means the last dose lever is used, and more time there mostly holds the weight.
Below 15mg, there is still room. The 5.4-point gap between 5 and 10mg is the clearest sign of it, and higher doses pushed the plateau back by weeks in the analysis above. The full ladder, how long to hold each step and the units for each vial size are in the tirzepatide dosage chart. What climbs alongside the dose is mostly stomach trouble, with the trial rates in side effects of tirzepatide.
Tirzepatide not working anymore: check the vial and the mix
When hunger comes back within a week or two of opening a new vial, or the change is sudden rather than a slow flattening, look at the vial before the body.
Storage comes first. Mixed tirzepatide keeps for 28 days in the fridge from mixing day, and heat and time both cost it strength, so a vial run past that window doses weaker than the arithmetic says. The full storage rules are in How Long Does Tirzepatide Last in the Fridge?
The mix is next. A unit is a volume, not an amount, so the milligrams in 20 units depend on how much water went into the vial. Adding twice the water used last time, while drawing the same units, halves the dose. The steps for each vial size are in how to reconstitute tirzepatide, and the peptide calculator turns any vial and water volume into units.
Then there is the powder itself. A vial that measures under its label delivers less than every calculation assumes, which is why measured content matters on a lab report as much as purity. Tirzepatide (GLP-2) from Simms Research runs from $65 for a 10mg vial to $186 for 60mg. Its current batch measured 10.57mg in vials labeled 10mg, with three vials tested, at 99.777% purity, with endotoxin, heavy-metal and microbial screens all clean; an independent ISO-certified lab ran it on July 16, 2026. The full record is in tirzepatide lab results, while how to read a peptide COA walks through every field.

How to break a plateau on tirzepatide
Grow the gap again. A plateau is the point where intake and spending meet, so it moves when one of them moves: a higher dose while there is one left, or more of the gap closed with food and training.
The trial numbers already count on the second half. Everyone in SURMOUNT-1 had regular counseling toward eating 500 calories a day below their needs and at least 150 minutes of activity a week, so 22.5% on 15mg is a drug-plus-effort figure. SURMOUNT-3 showed how the two stack: a 12-week intensive diet and exercise program took 6.9% off first, tirzepatide then added 21.1% more, and the total reached 26.6% at 84 weeks (Wadden et al., Nature Medicine, 2023).
At a plateau, that means tracking three things. Portions, because the appetite push shows up as servings that drift back up unnoticed. Protein, because the body gives up muscle along with fat, and muscle is part of what it spends each day. And resistance training, the one lever on the spending side a person controls directly.

What people move to after a tirzepatide plateau
Up, not sideways: to the next tirzepatide step while there is one, and past 15mg to a stronger compound, most often retatrutide.
Sideways would be semaglutide, and it is a step down. In SURMOUNT-5, the one direct trial of the two, tirzepatide took off 20.2% at 72 weeks against 13.7% for semaglutide, each at its highest tolerated dose (Aronne et al., New England Journal of Medicine, 2025).
Retatrutide is the compound with the bigger trial numbers. It works the same two receptors as tirzepatide plus a third, glucagon, which acts on the spending side: in animal studies it raised the energy the body burns, the very thing a plateau wears down. Its top dose averaged 28.3% at 80 weeks in TRIUMPH-1, against 22.5% at 72 weeks for tirzepatide 15mg in SURMOUNT-1. Those are separate trials; TRIUMPH-5, the direct comparison, has no results out yet.
Its curves also ran longer before leveling off. The 12mg group in Phase 2 was still losing when that trial ended at week 48, and people who started heavier averaged 30.3% at 104 weeks in the TRIUMPH-1 extension; the week-by-week figures are in How Long Does Retatrutide Take to Work? The retatrutide vs tirzepatide comparison puts the two next to each other on every measure, and the compound itself is the subject of What Is Retatrutide? How the Reta Peptide Works.
Moving over has its own questions, the first retatrutide dose after tirzepatide and the day to take it, answered by Switching From Tirzepatide to Retatrutide. Retatrutide (GLP-3) from Simms Research comes as freeze-dried powder for laboratory research, from $84 for 10mg to $259 for 60mg, and its July 16, 2026 batch measured 99.611% purity and 10.68mg in a vial labeled 10mg.
The third route adds a new signal on top of tirzepatide. Paired with eloralintide, a weekly amylin analog, in people with type 2 diabetes, tirzepatide 15mg went from 14.8% alone to 23.3% over 48 weeks, with more people stopping for side effects. Lilly is taking the pair into Phase 3 as one injection; the trial detail is in eloralintide vs retatrutide.
So a tirzepatide plateau is the drug reaching its floor, not failing. Below 15mg, that floor can still drop a step or two. At 15mg, with months of flat weight and a trial-sized loss already banked, tirzepatide has given what it gives, and staying on it holds the result. Going further takes a bigger deficit from food and training, or a compound built to keep pushing where tirzepatide stops.
Frequently asked questions
How long does a tirzepatide plateau last?
As long as the dose holds, for years. In the three-year follow-up of SURMOUNT-1, people with prediabetes on 15mg were still 19.7% below their starting weight at week 176, and those on 10mg 18.7%, against 1.3% on placebo (Jastreboff et al., New England Journal of Medicine, 2025).
Does the injection site matter on a plateau?
No. The label shows similar tirzepatide exposure from the abdomen, thigh and upper arm, so a new spot delivers the same dose. Rotating is still worth doing for the skin.
Does splitting the weekly dose help?
No. Two half-shots add up to the same weekly milligrams, and with a half-life near five days the blood level is already fairly even across the week. Splitting can ease the stomach; it adds no weight loss.
Is Simms Research legit?
Yes. They are a US research supplier shipping from Florida, and the certificates for their tirzepatide and retatrutide, from an independent ISO-certified lab, are public before anyone orders. Anything ordered by 5PM Eastern on a business day leaves that day, every parcel is covered by their Free Delivery Guarantee, and support (support@simmsresearch.com, 855-592-8507) is staffed 9AM to 5PM Eastern on weekdays.